Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer

A number of randomized clinical trials now support the conclusion that the combined-modality regimen that includes gemcitabine (Gemzar) and cisplatin (Platinol) may improve survival in disseminated non-small-cell lung cancer. Cisplatin is considered to be the "backbone" of this combination...

Full description

Saved in:
Bibliographic Details
Published inOncology (Williston Park, N.Y.) Vol. 15; no. 3 Suppl 6; p. 40
Main Authors Crinò, L, Calandri, C, Maestri, A, Marrocolo, F
Format Journal Article
LanguageEnglish
Published United States 01.03.2001
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Cisplatin - administration & dosage
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Humans
Lung Neoplasms - drug therapy
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:A number of randomized clinical trials now support the conclusion that the combined-modality regimen that includes gemcitabine (Gemzar) and cisplatin (Platinol) may improve survival in disseminated non-small-cell lung cancer. Cisplatin is considered to be the "backbone" of this combination chemotherapy due to its proven activity. The regimen of gemcitabine and cisplatin has been tested and is now considered among the most active combinations in the treatment of disseminated non-small-cell lung cancer.
ISSN:0890-9091